Seminars in Oncology
Volume 35, Supplement 3 , Pages S13-S21, June 2008

Antitumor Activity of Vinflunine: Effector Pathways and Potential for Synergies

  • Diane Braguer

      Affiliations

    • INSERM UMR911, Centre de Recherche en Oncologie Biologique, et Oncopharmacologie; Aix-Marseille University, Marseille, France.
    • Corresponding Author InformationAddress correspondence to Diane Braguer, PhD, Faculte de Pharmacié, INSERM UMR 911, 27 Boulevard Jean Moulin, 13005 Marseille, France.
    • ,
  • Jean-Marc Barret

      Affiliations

    • Centre de Recherche d'Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France.
    • ,
  • Hayley McDaid

      Affiliations

    • Albert Einstein College of Medicine, Bronx, NY.
    • ,
  • Anna Kruczynski

      Affiliations

    • Centre de Recherche d'Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Dr Braguer has no conflict of interest to declare. Dr McDaid has served as a consultant to Bristol-Myers Squibb. Drs Kruczynski and Barret are employees of the Institut de Recherche Pierre Fabre, a private pharmaceutical company supporting the development of vinflunine.

PII: S0093-7754(08)00023-7

doi:10.1053/j.seminoncol.2008.01.011

Seminars in Oncology
Volume 35, Supplement 3 , Pages S13-S21, June 2008

Article Tools

* Image Usage & Resolution